参考文献: Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 2020 Apr 30; haematol.2019.243790.doi:...
RefractorySignificant advancements have been achieved in the quality of treatment for relapsed/refractory multiple myeloma (RRMM). Currently, daratumumab (DARA) is a highly effective drug widely used for RRMM; however, the knowledge on its efficacy and safety in Japanese patients remains limited. ...
参考文献: (1)Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13): 1207-1219. (2)Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patie...
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. PMID: 32470437 Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. PMID: 29127588 Daratumumab: A Review in Combination Therapy ...
参考来源:Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Daratumumab subcutaneous formulation for the treatment of multiple myeloma. PMID: 32750265 Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. PMID: 26308596 Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, ...
Daratumumab (Darzalex®, Janssen) is a fully human IgG1 kappa monoclonal antibody targeting CD38 that has been approved by the FDA and EMA for the treatment of relapsed and refractory multiple myeloma in adult patients, either in monotherapy (approval in 2015–2016) or in combination with borte...
multiple myelomasequenceDaratumumab and elotuzumab have demonstrated improvements in overall response rates (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM). There is a lack of comparative clinical trials and an even larger lack of consensus on the optimal ...
Phase II study of daratumumab (DARA)monotherapy in patients with ≥ 3 lines of prior therapyor double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius)。(Abstract No: LBA8512)Session Type:Oral Abstract Session Background: DARA,a human anti-CD38 IgG1κ mAb, has single agent activity...
89%的患者对来那度胺耐药,71%的患者对硼替佐米(bortezomib)耐药,64%的患者对硼替佐米和来那度胺耐药。 参考文献: [1]FDA ApprovesDaratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed orRefractory Multiple Myeloma [2]Genmab官网...